Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 33,144 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: AR11, Placebo; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more

Conditions: Painful Lumbosacral Radiculopathy
Interventions: VX-548, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 54
States / cities: Phoenix, Arizona • Bakersfield, California • Banning, California + 48 more

Conditions: Rheumatoid Arthritis
Interventions: acalabrutinib, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 17
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 13 more

Conditions: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
Interventions: PF- 00610355, Placebo, Salmeterol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 30
States / cities: Fairhope, Alabama • San Diego, California • Spring Valley, California + 22 more

Conditions: Hypertriglyceridemia
Interventions: Amino acids, Placebo; Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 50 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Sleep Disturbance
Interventions: Melatonin 3 mg, Melatonin 0.5 mg, Cellulose placebo pill; Dietary Supplement · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
Interventions: Dalfampridine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cardiovascular Disease
Interventions: Rimonabant, Placebo (for Rimonabant); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older
Enrollment: 18,695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Quality of Life, Pelvic Organ Prolapse, Prolapses, Vaginal Vault
Interventions: Dexamethasone, Normal saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Lyme Borreliosis
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more

Conditions: Marijuana Impairment
Interventions: Low dose THC marijuana, High dose THC marijuana, Placebo marijuana; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more

Conditions: Parkinson's Disease
Interventions: Placebo, IPX066 95 mg LD, IPX066 145 mg LD, IPX066 195 mg LD, IPX066 245 mg LD; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Garden Grove, California + 22 more

Conditions: Desmoid, Desmoid Tumor
Interventions: AL102, Placebo; Drug · Other
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 23
States / cities: Pheonix, Arizona • Duarte, California • Santa Monica, California + 17 more

Conditions: Diabetes Mellitus Type II
Interventions: Placebo, Calcium polycarbophil; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Duration of Interscalene Block
Interventions: ropivacaine plus dexamethasone anesthetic, ropivacaine plus saline plus dexamethasone anesthetic; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Concussion, Mild
Interventions: Pro2Cool Device, Sham Cooling Garment Device; Device
Lead sponsor: TecTraum Inc.; Industry
Eligibility: 13 Years to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Akron, Ohio • Cleveland, Ohio

Conditions: Atopic Asthma
Interventions: abatacept, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Islet Transplantation in Diabetes Mellitus Type 1
Interventions: Reparixin, Placebo; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Injury of Kidney, Acute Renal Failure
Interventions: I5NP (a small interfering RNA), placebo; Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Cleveland, Ohio + 3 more

Conditions: Refractory Partial Seizures
Interventions: Rufinamide; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 12 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Healthy
Interventions: TP-05 (lotilaner oral capsules), Placebo; Drug
Lead sponsor: Tarsus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hepatitis C Virus
Interventions: BMS-790052, Placebo, peginterferon alfa-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 35
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 47
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more

Search by objective public record fields.

Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

Effects of Amino Acids on Regional Lipid Metabolism

Feasibility Study of Personalized Trials to Improve Sleep Quality

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Neuroscience of Marijuana Impaired Driving

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

A Study of AL102 in Patients With Progressing Desmoid Tumors

Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study

The Effect of Systemic or Perineural Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine

Pro-2-Cool Pivotal Trial II

The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

A Pharmacokinetic Study of TP-05 in Healthy Subjects

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)